Colchicine for Patients With Chagas´ Disease( B1 Stage)

Effect of Colchicine on Inflammation and Myocardial Fibrosis Assessed by Magnetic Resonance Imaging in Patients With Chagas' Heart Disease

This study evaluate the addition of colchicine in the treatment of patients with Chagas´disease.

Forty patients will receive colchicine while twenty patients will receive placebo

Chagas disease is considered one of the main cause of dilated cardiomyopathy in Latin America. The histopathological characteristics of Chagas' disease are the presence of myocarditis, destruction of heart fibers, and severe myocardial fibrosis. Colchicine had a protective effect on myocardium, indicated by decreased interstitial myocardial fibrosis and attenuated myocardial inflammation. It is an inflammatory cause of cardiomyopathy and myocardial fibrosis is the hallmark of this disease. Colchicine is a drug used in inflammatory diseases, and could also act on myocardial remodeling interfering in the synthesis of collagen

Inclusion Criteria:

• Clinical and serological diagnosis of Chagas´disease ( Stage B1)
• Must be able to swallow tablets

Exclusion Criteria:

• myocardial infarction or coronary artery disease,
• diabetes mellitus,
• valvular disease,
• creatinine clearance <30 ml / kg / min
• contraindication to perform cardiac magnetic resonance imaging
• use of angiotensin converting enzyme inhibitors, angiotensin II receptor blockers and aldosterone blockers
• previous use of benzonidazole